China's 'Two Sessions': Vaccines, Drugs Seen Key To Easing Restrictions Amid New Spike
Boosters Needed But mRNA Options Lag
The latest policies from Beijing show that the Chinese government is readying its own new vaccines and drugs for COVID-19 in a bid to gradually ease some of the strictest pandemic restrictions globally, but progress is mixed and domestic reported infections are surging to their highest level since March 2020.
You may also be interested in...
CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.
Hong Kong is having to take drastic new measures, including a vaccine mandate, to fight a rapid surge in COVID-19 cases amid its strict "COVID zero" policies, which might signal potential challenges in the mainland. Meanwhile, US mRNA vaccine developer Moderna has announced an expansion in Asia.
In a surprise move, China has conditionally approved Pfizer’s oral COVID-19 antiviral Paxlovid, a development that may have far-reaching consequences for the country's pandemic policies and domestic drug developers.